Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CYTO
- Price
- 0.12
- Stock movement down
- -0.28 (-69.67%)
- Company name
- Altamira Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 452.67K
- Ent value
- 1.07M
- Price/Sales
- 8.58
- Price/Book
- 0.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -69.69%
- 1 year return
- -95.56%
- 3 year return
- -93.89%
- 5 year return
- -81.68%
- 10 year return
- -77.00%
Last updated: 2025-04-11
DIVIDENDS
CYTO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.58 |
| Price to Book | 0.07 |
| EV to Sales | 20.31 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.78M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 52.73K |
| Gross profit (TTM) | -53.36K |
| Operating income (TTM) | -2.29M |
| Net income (TTM) | -2.71M |
| EPS (TTM) | - |
| EPS (1y forward) | -1.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -101.18% |
| Operating margin (TTM) | -4348.49% |
| Profit margin (TTM) | -5139.89% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 617.41K |
| Net receivables | 74.82K |
| Total current assets | 1.22M |
| Goodwill | 0.00 |
| Intangible assets | 3.89M |
| Property, plant and equipment | 0.00 |
| Total assets | 7.69M |
| Accounts payable | 413.11K |
| Short/Current long term debt | 99.66K |
| Total current liabilities | 888.91K |
| Total liabilities | 1.24M |
| Shareholder's equity | 6.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -3.86M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -3.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -41.97% |
| Return on Assets | -35.23% |
| Return on Invested Capital | -41.33% |
| Cash Return on Invested Capital | -58.82% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.14 |
| Daily high | 0.20 |
| Daily low | 0.10 |
| Daily Volume | 745K |
| All-time high | 623200.00 |
| 1y analyst estimate | 5.05 |
| Beta | 2.44 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 16 May 2025 |
Downside potential
Loading...
Downside potential data
| CYTO | S&P500 | |
| Current price drop from All-time high | -100.00% | -2.74% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -85.97% | -11.07% |
| Avg time to new high | 373 days | 12 days |
| Max time to new high | 2255 days | 1805 days |
COMPANY DETAILS
Marketcap
452.67K
Marketcap category
Small-cap
Description
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Employees
10
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner